Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease.

The high rate of severe cytomegalovirus (CMV) disease after bone marrow transplantation (BMT) is related to the profound immunodeficiency posttransplant. Because cytotoxic T lymphocytes (CTL) have been implicated in resistance to viral infections, we examined the restoration of the CMV-specific CTL response in 20 patients who received bone marrow from HLA-matched, CMV-seropositive donors. Blood specimens were obtained from patients at 1, 2, and 3 months after BMT and from the donors on a single occasion. Peripheral blood mononuclear cells were cocultured with CMV-infected donor-derived fibroblasts for 2 weeks and then tested for cytotoxicity against CMV-infected and uninfected autologous or HLA-mismatched fibroblasts. Cytolytic activity was detected in all 20 donors, with specificity for autologous CMV-infected targets demonstrable in 17 (median CMV-specific lysis at an effector:target ratio of 15:1 was 32%, range 18% to 83%). Specific lysis was mediated by CD8+, class I-restricted T cells, as shown by inhibition with anti-class I monoclonal antibody and by selective depletion of effector cells. By contrast, CMV-specific CTL were detected in only 10 of 20 patients after BMT (median lysis 29% at 3 months post-BMT). None of these 10 patients developed CMV pneumonia, whereas 6 of the 10 patients with an undetectable CMV-specific CTL response after BMT died with CMV pneumonia. These results demonstrate that restoration of CMV-specific CTL responses may require an extended time period after BMT in some patients, and that such patients are at increased risk of developing severe CMV disease. Approaches to reconstitute CMV immunity in BMT patients by adoptive transfer of CMV-specific CD8+ CTL clones derived from the bone marrow donor are now being pursued.

[1]  W. Britt,et al.  Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression. , 1991, Journal of immunology.

[2]  P. Greenberg Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. , 1991, Advances in immunology.

[3]  H. Kodo,et al.  [Cytomegalovirus pneumonia after bone marrow transplantation]. , 1990, Nihon rinsho. Japanese journal of clinical medicine.

[4]  J. Meyers,et al.  Cytomegalovirus infection after autologous bone marrow transplantation: occurrence of cytomegalovirus disease and effect on engraftment. , 1990, Blood.

[5]  S. Riddell,et al.  The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. , 1990, Journal of immunological methods.

[6]  K. Atkinson,et al.  Reconstruction of the haemopoietic and immune systems after marrow transplantation. , 1990, Bone marrow transplantation.

[7]  B. Dörken,et al.  T-cell ontogeny after autologous bone marrow transplantation: failure to synthesize interleukin-2 (IL-2) and lack of CD2- and CD3-mediated proliferation by both CD4- and CD8+ cells even in the presence of exogeneous IL-2. , 1989, Blood.

[8]  M. Martelli,et al.  Lymphokine production by T-cell clones after human bone marrow transplantation. , 1989, Blood.

[9]  G. Heller,et al.  Immune reconstitution following bone marrow transplantation: comparison of recipients of T-cell depleted marrow with recipients of conventional marrow grafts. , 1989, Blood.

[10]  H. Deeg,et al.  Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. , 1989, Blood.

[11]  A. Nademanee,et al.  Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients. , 1988, Transplantation.

[12]  E. Reed,et al.  Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. , 1988, Annals of internal medicine.

[13]  J. Sissons,et al.  Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses , 1988, The Journal of experimental medicine.

[14]  H. Deeg,et al.  Serum cyclosporine concentration and risk of acute graft-versus-host disease after allogeneic marrow transplantation. , 1988, The New England journal of medicine.

[15]  S. Spector,et al.  Generation of human cytomegalovirus-specific cytotoxic T-lymphocytes in a short-term culture. , 1988, Journal of immunological methods.

[16]  S. Jonjić,et al.  A nonstructural viral protein expressed by a recombinant vaccinia virus protects against lethal cytomegalovirus infection , 1988, Journal of virology.

[17]  U. Koszinowski,et al.  Failure in generating hemopoietic stem cells is the primary cause of death from cytomegalovirus disease in the immunocompromised host , 1988, The Journal of experimental medicine.

[18]  J. Sissons,et al.  Human cytomegalovirus‐specific cytotoxic T cells: their precursor frequency and stage specificity , 1988, European journal of immunology.

[19]  M. Thornquist,et al.  Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. , 1988, The New England journal of medicine.

[20]  K. Okuno,et al.  Requirements for T cell recognition and elimination of retrovirally-transformed cells. , 1988, Princess Takamatsu symposia.

[21]  U. Koszinowski,et al.  CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity , 1987, Journal of virology.

[22]  M. Oldstone,et al.  Recent clinical isolates of cytomegalovirus suppress human cytomegalovirus-specific human leukocyte antigen-restricted cytotoxic T-lymphocyte activity , 1986, Journal of virology.

[23]  G. Trinchieri,et al.  Requirement for HLA-DR+ accessory cells in natural killing of cytomegalovirus-infected fibroblasts , 1986, The Journal of experimental medicine.

[24]  R. Miller,et al.  Long-lasting deficit of functional T cell precursors in human bone marrow transplant recipients revealed by limiting dilution methods. , 1986, Journal of immunology.

[25]  N. Flournoy,et al.  Risk factors for cytomegalovirus infection after human marrow transplantation. , 1986, The Journal of infectious diseases.

[26]  J. Sissons,et al.  Cytomegalovirus - its cellular immunology and biology. , 1986, Immunology today.

[27]  A. Rimm,et al.  Interstitial pneumonitis after bone marrow transplantation. Assessment of risk factors. , 1986, Annals of internal medicine.

[28]  D. Johnston,et al.  Immune recovery following allogeneic bone marrow transplantation. , 1985, Transplantation.

[29]  S. Jonjić,et al.  Interstitial murine cytomegalovirus pneumonia after irradiation: characterization of cells that limit viral replication during established infection of the lungs , 1985, Journal of virology.

[30]  R. Storb,et al.  Cellular interactions in marrow-grafted patients. III. Normal interleukin 1 and defective interleukin 2 production in short-term patients and in those with chronic graft-versus-host disease. , 1985, Transplantation.

[31]  H. Deeg,et al.  RECOVERY OF IN VIVO CELLULAR IMMUNITY AFTER HUMAN MARROW GRAFTING: Influence of Time Postgrafting and Acute Graft‐Versus‐Host Disease , 1984, Transplantation.

[32]  J. Biggs,et al.  Human bone marrow allograft recipients: production of, and responsiveness to, interleukin 2. , 1983, Journal of immunology.

[33]  R. Storb,et al.  Allogeneic Bone‐Marrow Transplantation , 1983, Immunological reviews.

[34]  R. Storb,et al.  Cellular interactions in marrow-grafted patients. I. Impairment of cell-mediated lympholysis associated with graft-vs-host disease and the effect of interleukin 2. , 1983, Journal of immunology.

[35]  L. Borysiewicz,et al.  Human cytomegalovirus‐specific cytotoxic T lymphocytes: requirements for in vitro generation and specificity , 1983, European journal of immunology.

[36]  J. Manischewitz,et al.  Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. , 1982, The New England journal of medicine.

[37]  P. Parham,et al.  Monomorphic anti-HLA-A,B,C monoclonal antibodies detecting molecular subunits and combinatorial determinants. , 1982, Journal of immunology.

[38]  J. Manischewitz,et al.  HLA-restricted cytotoxic T lymphocyte and nonthymic cytotoxic lymphocyte responses to cytomegalovirus infection of bone marrow transplant recipients. , 1981, Journal of immunology.

[39]  N. Flournoy,et al.  Cytomegalovirus infection and specific cell-mediated immunity after marrow transplant. , 1980, The Journal of infectious diseases.

[40]  J. Waner,et al.  Blastogenic response of human lymphocytes to human cytomegalovirus. , 1977, Clinical and experimental immunology.

[41]  R Storb,et al.  Bone-marrow transplantation (first of two parts). , 1975, The New England journal of medicine.